DOC1021 (NCT06805305)

Name: DOC1021 trial for Glioblastoma (GBM) (NCT06805305)
Uploaded: 2026-10-31T22:29:57.049Z
Duration: 1 min 29 s
Description: DOC1021 trial for Glioblastoma (GBM) (NCT06805305). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06805305.

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM): a one-minute explainerNCT068053051 min

DOC1021 trial for Glioblastoma (GBM) (NCT06805305). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with newly diagnosed IDH-wildtype glioblastoma suitable for substantial tumor removal, temozolomide, and radiation.

The idea: DOC1021 is a dendritic-cell vaccine loaded with tumor material and messenger RNA. Randomization compares standard treatment alone with standard treatment plus DOC1021/pIFN. The vaccine group receives filgrastim, blood-cell collection, three injections near neck lymph nodes two weeks apart, and six weekly pIFN injections. Both groups receive surgery, temozolomide, and six weeks of radiation. Researchers compare survival and safety.

This phase 2 study plans 180 patients. Diakonos Oncology sponsors; seventeen US sites recruit.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.